---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002059"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:11:58.928442+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunome licenses Zentalis' ROR1 ADC ZPC-21 and ADC platform for $35M upfront, up to $275M milestones

## Summary
- Exclusive worldwide license for preclinical ROR1 ADC ZPC-21; IND submission targeted for 1Q 2025.
- Upfront consideration: $35M in cash and Immunome common stock (2,298,586 shares).
- Zentalis eligible for up to $275M in milestone payments plus mid-to-high single-digit royalties.
- Immunome gains Zentalis' proprietary ADC platform technology for additional programs.
- Zentalis agrees to standstill restrictions and share transfer limitations for one year.

## SEC filing metadata
- accession: 0001104659-24-002059
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924002059/0001104659-24-002059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924002059/tm242340d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002059
- JSON: https://secwatch.observer/filing/0001104659-24-002059.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002059.txt

## Key facts
- Material Agreements
  Immunome Inc. entered into Stock Issuance Agreement with Zentalis Pharmaceuticals, Inc. (effective 2024-01-05).
  - Action: entry
  - Agreement: license
  - Counterparty: Zentalis Pharmaceuticals, Inc.
  - Effective: 2024-01-05
  source text: Concurrently with the execution of the License Agreement, the Company entered into a stock issuance agreement (the “Stock Issuance Agreement”) with Zentalis, pursuant to which the Company issued 2,298,586 shares of the Company’s common stock (the “Shares”), as partial consideration for the rights licensed to the Company from Zentalis pursuant to the License Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465924002059/0001104659-24-002059-index.htm
- Material Agreements
  Immunome Inc. entered into License Agreement with Zentalis Pharmaceuticals, Inc. valued at $35 million (effective 2024-01-05).
  - Action: entry
  - Agreement: license
  - Counterparty: Zentalis Pharmaceuticals, Inc.
  - Value: $35 million
  - Effective: 2024-01-05
  source text: On January 5, 2024, Immunome, Inc. (the “Company”) entered into a license agreement (“License Agreement”) with Zentalis Pharmaceuticals, Inc. (“Zentalis”), pursuant to which the Company received an exclusive, worldwide, royalty-bearing, sublicensable license under certain intellectual property relating to Zentalis’ proprietary antibody-drug conjugate (“ADC”) platform technology, ROR1 antibodies and ADCs targeting ROR1 to exploit products covered by or incorporating the licensed intellectual property rights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465924002059/0001104659-24-002059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.